S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:PASG

Passage Bio Stock Forecast, Price & News

$19.83
+0.40 (+2.06 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.50
Now: $19.83
$19.91
50-Day Range
$17.61
MA: $21.33
$29.83
52-Week Range
$8.09
Now: $19.83
$38.23
Volume373,501 shs
Average Volume508,107 shs
Market Capitalization$910.53 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (Ã-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin for the treatment of FTD caused by a deficiency of progranulin; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase, for infantile Krabbe disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
Passage Bio logo

Headlines

Passage Bio Inc to Host Earnings Call
March 3, 2021 |  finance.yahoo.com
Passage Bio, Inc. Rings the Closing Bell
March 1, 2021 |  nasdaq.com
Here's Why Shares of Passage Bio Dropped Today
January 22, 2021 |  finance.yahoo.com
Passage Bio Announces Pricing of Public Offering
January 21, 2021 |  finance.yahoo.com
Passage Bio Announces Launch of Proposed Public Offering
January 19, 2021 |  finance.yahoo.com
Is PASG A Good Stock To Buy Now?
December 15, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PASG
CUSIPN/A
CIKN/A
Phone267-866-0311
Employees20
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$910.53 million
Next Earnings Date5/10/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.93 out of 5 stars

Medical Sector

93rd out of 1,972 stocks

Biological Products, Except Diagnostic Industry

9th out of 177 stocks

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$19.83
+0.40 (+2.06 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PASG News and Ratings via Email

Sign-up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Passage Bio (NASDAQ:PASG) Frequently Asked Questions

Is Passage Bio a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Passage Bio stock.
View analyst ratings for Passage Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Passage Bio?

Wall Street analysts have given Passage Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Passage Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Passage Bio's next earnings date?

Passage Bio is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Passage Bio
.

How were Passage Bio's earnings last quarter?

Passage Bio, Inc. (NASDAQ:PASG) posted its quarterly earnings data on Tuesday, March, 2nd. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by $0.14.
View Passage Bio's earnings history
.

How has Passage Bio's stock price been impacted by Coronavirus (COVID-19)?

Passage Bio's stock was trading at $18.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PASG shares have increased by 5.1% and is now trading at $19.83.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PASG?

8 brokerages have issued 12 month price objectives for Passage Bio's stock. Their forecasts range from $2.21 to $35.00. On average, they expect Passage Bio's stock price to reach $25.53 in the next twelve months. This suggests a possible upside of 28.7% from the stock's current price.
View analysts' price targets for Passage Bio
or view top-rated stocks among Wall Street analysts.

Who are Passage Bio's key executives?

Passage Bio's management team includes the following people:
  • Dr. Bruce A. Goldsmith M.B.A., Ph.D., CEO, Pres & Director (Age 55, Pay $485.72k)
  • Dr. Stephen P. Squinto, Co-Founder, Acting Head of R&D and Director (Age 65, Pay $786.99k)
  • Ms. Jill M. Quigley Esq., J.D., Chief Operating Officer (Age 45, Pay $756.38k)
  • Dr. Gary Romano M.D., Ph.D., Chief Medical Officer (Age 59, Pay $519.77k)
  • Dr. James M. Wilson M.D., Ph.D., Co-Founder & Chief Scientific Advisor (Age 66)
  • Mr. Richard S. Morris, Chief Financial Officer (Age 47)
  • Mr. Alexandros Fotopoulos MSc, MBA, Chief Technical Officer (Age 52)
  • Mr. Edgar B. Cale Esq., J.D., Gen. Counsel & Company Sec. (Age 57)
  • Robin DeRogatis, VP HR

Who are some of Passage Bio's key competitors?

What other stocks do shareholders of Passage Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include Alector (ALEC), NVIDIA (NVDA), Advanced Micro Devices (AMD), DocuSign (DOCU), Intel (INTC), Alteryx (AYX), Gossamer Bio (GOSS), JD.com (JD), Micron Technology (MU) and Black Diamond Therapeutics (BDTX).

When did Passage Bio IPO?

(PASG) raised $126 million in an initial public offering (IPO) on Friday, February 28th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Chardan was co-manager.

What is Passage Bio's stock symbol?

Passage Bio trades on the NASDAQ under the ticker symbol "PASG."

Who are Passage Bio's major shareholders?

Passage Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.82%), Highline Capital Management L.P. (1.31%), Morgan Stanley (0.92%), Emerald Advisers LLC (0.74%), Alyeska Investment Group L.P. (0.63%) and Alyeska Investment Group L.P. (0.63%). Company insiders that own Passage Bio stock include Alexandros Fotopoulos, Athena Countouriotis, Bruce A Goldsmith, Jill M Quigley, Life Sciences Ix LP Frazier and Thomas Woiwode.
View institutional ownership trends for Passage Bio
.

Which institutional investors are selling Passage Bio stock?

PASG stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Baker BROS. Advisors LP, Swiss National Bank, Squarepoint Ops LLC, State of Wisconsin Investment Board, Alyeska Investment Group L.P., Alyeska Investment Group L.P., and Emerald Advisers LLC.
View insider buying and selling activity for Passage Bio
or view top insider-selling stocks.

Which institutional investors are buying Passage Bio stock?

PASG stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Ikarian Capital LLC, Northern Trust Corp, Victory Capital Management Inc., Norges Bank, Charles Schwab Investment Management Inc., and Bank of New York Mellon Corp. Company insiders that have bought Passage Bio stock in the last two years include Alexandros Fotopoulos, Athena Countouriotis, Bruce A Goldsmith, Jill M Quigley, Life Sciences Ix LP Frazier, and Thomas Woiwode.
View insider buying and selling activity for Passage Bio
or or view top insider-buying stocks.

How do I buy shares of Passage Bio?

Shares of PASG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Passage Bio's stock price today?

One share of PASG stock can currently be purchased for approximately $19.83.

How much money does Passage Bio make?

Passage Bio has a market capitalization of $910.53 million.

How many employees does Passage Bio have?

Passage Bio employs 20 workers across the globe.

What is Passage Bio's official website?

The official website for Passage Bio is www.passagebio.com.

Where are Passage Bio's headquarters?

Passage Bio is headquartered at TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103.

How can I contact Passage Bio?

Passage Bio's mailing address is TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103. The company can be reached via phone at 267-866-0311 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.